| scholarly article | Q13442814 |
| P50 | author | R. Andrew Byrd | Q58325964 |
| Lino Tessarollo | Q67472644 | ||
| P2093 | author name string | Richard J Wenstrup | |
| Neil Hunter | |||
| Ranabir Das | |||
| Shyam K Sharan | |||
| Eileen Southon | |||
| Stacey Stauffer | |||
| Karla R Bowles | |||
| Kajal Biswas | |||
| Benjamin B Roa | |||
| Sandra S Burkett | |||
| Betty K Martin | |||
| Huanyu Qiao | |||
| Dmitry Pruss | |||
| Susan L North | |||
| Julie M Eggington | |||
| Scott C Sizemore | |||
| P2860 | cites work | Interactions between human BRCA2 protein and the meiosis-specific recombinase DMC1 | Q24307601 |
| Structural basis for recruitment of BRCA2 by PALB2 | Q24315745 | ||
| XRCC3 promotes homology-directed repair of DNA damage in mammalian cells | Q24597771 | ||
| Meta-analysis of BRCA1 and BRCA2 penetrance | Q24654786 | ||
| Simple and highly efficient BAC recombineering using galK selection | Q24794075 | ||
| BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure | Q27639649 | ||
| Coot: model-building tools for molecular graphics | Q27860505 | ||
| UCSF Chimera--a visualization system for exploratory research and analysis | Q27860666 | ||
| A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay | Q28118199 | ||
| Unraveling the mechanism of BRCA2 in homologous recombination | Q28242443 | ||
| Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to gamma-radiation and premature senescence | Q28509372 | ||
| Involvement of Brca2 in DNA repair | Q28589746 | ||
| ESEfinder: A web resource to identify exonic splicing enhancers | Q29616126 | ||
| The mouse Spo11 gene is required for meiotic chromosome synapsis | Q29618404 | ||
| Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium | Q29619206 | ||
| Classifying Variants of Undetermined Significance in BRCA2 with protein likelihood ratios. | Q30373569 | ||
| Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2 | Q80140639 | ||
| Embryonic stem cells deficient for Brca2 or Blm exhibit divergent genotoxic profiles that support opposing activities during homologous recombination | Q80334385 | ||
| Systematic identification and analysis of exonic splicing silencers. | Q33210154 | ||
| An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers | Q33249150 | ||
| Genetic evidence and integration of various data sources for classifying uncertain variants into a single model | Q33379396 | ||
| A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example | Q33475933 | ||
| Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2 | Q33910123 | ||
| Functional assays for classification of BRCA2 variants of uncertain significance | Q34116524 | ||
| Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality | Q34135443 | ||
| Breast cancer genetics: what we know and what we need | Q34236139 | ||
| Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. | Q34541051 | ||
| Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. | Q34581303 | ||
| Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results | Q34788325 | ||
| A simple two-step, 'hit and fix' method to generate subtle mutations in BACs using short denatured PCR fragments | Q35222962 | ||
| A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). | Q35622910 | ||
| Functional assays for BRCA1 and BRCA2. | Q35775886 | ||
| BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers | Q36335840 | ||
| Functional redundancy of exon 12 of BRCA2 revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant | Q36408445 | ||
| A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes | Q36492194 | ||
| Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations | Q37011738 | ||
| Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2 | Q37092814 | ||
| Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance | Q37117082 | ||
| A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history | Q37205554 | ||
| Assessment of functional effects of unclassified genetic variants | Q37308298 | ||
| Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations | Q37363083 | ||
| The contribution of BRCA1 and BRCA2 to ovarian cancer | Q37453854 | ||
| Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. | Q41985080 | ||
| BRCA phenocopies or ascertainment bias? | Q43232466 | ||
| Analysis of Fgf8 gene function in vertebrate development | Q46135598 | ||
| Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals | Q46796026 | ||
| Synaptonemal complex proteins: occurrence, epitope mapping and chromosome disjunction | Q48078764 | ||
| Colocalisation of predicted exonic splicing enhancers in BRCA2 with reported sequence variants. | Q52582443 | ||
| A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. | Q52599103 | ||
| THE GENETICS OF BREAST CANCER SUSCEPTIBILITY | Q57272243 | ||
| Clinical Classification ofBRCA1andBRCA2DNA Sequence Variants: The Value of Cytokeratin Profiles and Evolutionary Analysis—A Report From the kConFab Investigators | Q57306048 | ||
| The BRCA2 c.9004G>A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent | Q58325168 | ||
| A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family | Q74427899 | ||
| Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations | Q78105304 | ||
| P433 | issue | 18 | |
| P921 | main subject | embryonic stem cell | Q1151519 |
| P304 | page(s) | 3993-4006 | |
| P577 | publication date | 2012-06-07 | |
| P1433 | published in | Human Molecular Genetics | Q2720965 |
| P1476 | title | Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay | |
| P478 | volume | 21 |
| Q48128057 | A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors |
| Q41084246 | Acquired cross-linker resistance associated with a novel spliced BRCA2 protein variant for molecular phenotyping of BRCA2 disruption. |
| Q50210067 | Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches |
| Q38914005 | BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer |
| Q34518167 | BRCA2 regulates DMC1-mediated recombination through the BRC repeats. |
| Q94562670 | Bypass of premature stop codons and generation of functional BRCA2 by exon skipping |
| Q53101648 | Capillary electrophoresis analysis of conventional splicing assays: IARC analytical and clinical classification of 31 BRCA2 genetic variants. |
| Q51062318 | Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes. |
| Q104466347 | Epidemiological and ES cell-based Functional Evaluation of BRCA2 Variants Identified in Families with Breast Cancer |
| Q41499215 | Exceptions to the rule: case studies in the prediction of pathogenicity for genetic variants in hereditary cancer genes |
| Q37715826 | Functional assays for analysis of variants of uncertain significance in BRCA2. |
| Q64080586 | Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer |
| Q92785287 | HSF2BP negatively regulates homologous recombination in DNA interstrand crosslink repair |
| Q38925408 | Hereditary breast and ovarian cancer: new genes in confined pathways |
| Q28085364 | Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins |
| Q27308072 | Interaction with PALB2 Is Essential for Maintenance of Genomic Integrity by BRCA2 |
| Q28085603 | Molding BRCA2 function through its interacting partners |
| Q53310020 | Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers. |
| Q38685850 | Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study |
| Q55280273 | Prevalence of deleterious mutations among patients with breast cancer referred for multigene panel testing in a Romanian population. |
| Q36538025 | Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland |
| Q37011944 | Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil |
| Q89486038 | The functional impact of variants of uncertain significance in BRCA2 |
| Q89014443 | The impact of variant classification on the clinical management of hereditary cancer syndromes |
| Q33820594 | Two decades after BRCA: setting paradigms in personalized cancer care and prevention |
Search more.